Eli Lilly (LLY) Stock: Slips 2.54% Despite Promising Phase 1 Ovarian Cancer Results

TLDR LLY stock drops 2.54% to $1,273.46 despite upbeat ovarian cancer trial data. Sofe-M combination delivers a 79.3% response rate in Phase 1 ovarian cancer study. All evaluable patients achieved disease control in Lilly’s early-stage trial. Severe neutropenia affected 42% as dose reductions reached 42% in the study. Lilly advances Sofe-M into three Phase 3 [...]

The post Eli Lilly (LLY) Stock: Slips 2.54% Despite Promising Phase 1 Ovarian Cancer Results appeared first on Blockonomi.